New therapeutic options for the treatment of ankylosing spondylitis.

The pathogenesis of spondyloarthritis (SpA) is multifactorial and involves multiple immune cells cytokines that are signaled by Janus kinase (JAK). Inhibition JAK signaling pathways has emerged as a new therapeutic option for patients with inflammatory joint diseases. Despite the proven effect treatment anti-IL-17, well TNFα inhibitors, some ankylosing spondylitis cannot reach minimal disease activity or remission. This necessitated development class molecules, in recent years more clinical studies have their role both rheumatoid arthritis spondylitis. inhibition promising strategy SpA its application potential axial, polyarticular, extraarticular manifestations psoriatic spondylitis.
 present literature review aims to highlight options offered this target synthetic disease-modifying antirheumatic drugs summarize trial data tofacitinib, upadacitinib filgotinib reported date.